

Polycavernoside C and C2, the new analogs of the human lethal toxin polycavernoside A, from the red alga, *Gracilaria edulis*

Mari Yotsu-Yamashita,^{a,*} Kazumi Abe,^a Tetsuya Seki,^a Kenshu Fujiwara^b
and Takeshi Yasumoto^c

^aGraduate School of Agricultural Science, Tohoku University, Tsutsumidori-Amamiya, Aoba-ku, Sendai 981-8555, Japan

^bDivision of Chemistry, Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan

^cJapan Food Research Laboratories, Tama Laboratory, 6-11-10 Nagayama, Tama-shi, Tokyo 206-0025, Japan

Received 21 January 2007; accepted 1 February 2007

Available online 7 February 2007

Abstract—Two new analogs of the human lethal toxin polycavernoside A, polycavernoside C and C2 (0.1–0.2 mg for each), were isolated from the red alga, *Gracilaria edulis*. The relative stereostructure of polycavernoside C and the absolute structure of polycavernoside C2 were determined by spectroscopic analysis and synthesis of the model of their aglycon.

© 2007 Elsevier Ltd. All rights reserved.

Polycavernoside A (PA, Fig. 1) and B (PB) were isolated as the causative toxins of the human fatal poisoning (3 death/15 patients) which occurred in Guam in 1991, resulting from ingestion of the red alga, *Gracilaria edulis*.^{1,2} PA was also identified from the same alga and *Acanthophora specifera*, which also caused fatal poisoning (8 death/36 patients) in Philippines in 2002–2003.³ We determined the planar structures of PA¹ and the analogs, PA2, PA3, PB, and PB2,⁴ which possess the same macrolide aglycon structure. Structural variation among these analogs are in the conjugated diene or triene side chain at C15, and in O-methylated or O-acetylated L-fucosyl-D-xylose sugar part at C5. The total synthesis of (–)-PA was achieved by three groups,^{5–7} and the absolute structure of PA was established by Fujiwara and Murai et al.⁵ Further synthetic efforts have been continuously reported.⁸ The study of structure–activity relationship⁹ and pharmacological details of PA are now progressing.¹⁰ We isolated two other minor analogs, polycavernoside C (PC, **1**) and C2 (PC2, **2**) (0.1–0.2 mg for each), from *G. edulis* in 1992–1994 collected in Guam. These were suggested to have a common aglycon structure, and to be the first analogs which have the different aglycon structure from that of PA. Here we report the relative stereostructure of **1** and the absolute structure of **2** deduced by spectroscopic analysis and synthesis of the model of their aglycon (**3b**).

Compound **1** (0.1–0.2 mg) was isolated together with PA (0.2 mg) and PB (0.1 mg), from *G. edulis* (4 kg) collected on June 25, 1991 in Guam, while **2** (0.1–0.2 mg) was isolated from the same alga (2 kg, June 11, 1992) with PA (0.4 mg), PA2 (0.1 mg), PA3 (0.4 mg), and PB2 (0.1 mg),⁴ by successive normal and reversed phase chromatography as reported previously.^{1,4} Elution of **1** and **2** from the columns was monitored by diode array UV detector. For final separation of **1** from PB,¹ Capcell pack CN (H₂O–MeCN from 1:1 to 0:10) was used, and **1** was eluted before PB. Compound **2** was eluted after PA2, PB2, and PA from the final column, Develosil ODS-5 (H₂O–MeCN 1:3)⁴ and further purified on the same column. Compound **2** has been kept intact until now after storage in CD₃CN at –20 °C for more than 10 years, while **1** was decomposed in pyridine-*d*₅. Thus, **2** was mainly used for the structural analysis of the common aglycon of **1** and **2**.

Compound **1** was found to have a molecular weight 856 as determined from FABMS [M–H₂O+H]⁺ *m/z* 839, [M+Na]⁺ *m/z* 879, [M+K]⁺ *m/z* 895. **2** was found to have a molecular formula of C₄₅H₇₄O₁₅ by HR-FAB MS ([M+Na]⁺ 877.4930, Δ+0.5 mmu). ¹H NMR spectra and ¹H–¹H COSY of **1** and **2** (CD₃CN), and UV absorption (λ_{max} 220 nm for **1**, 259, 270, 280 nm for **2**, MeCN) suggested the presence of conjugated diene for **1** and conjugated triene for **2**. The ³J_{HH} values (16 Hz for **1**, 15.4 Hz for **2**) indicated *E, E* and *E, E, E* geometry for **1** and **2**, respectively. The same disaccharide

* Corresponding author. E-mail: myama@biochem.tohoku.ac.jp

Table 1. NMR spectral data of **1**, **2** and **3b** in CD₃CN

Pos	1			2			¹³ C (ppm)	3b			¹³ C (ppm)
	¹ H (ppm)	Mult.	<i>J</i> (Hz)	¹ H (ppm)	Mult.	<i>J</i> (Hz)		¹ H (ppm)	Mult.	<i>J</i> (Hz)	
1							—				170
2	2.18	t	12	2.19	m		—	2.20	m		40
	2.62	dd	12, 3	2.62	dd	13.8, 3.0		2.62	dd	13.8, 2.9	
3	3.40	m		3.41	m		81	3.41	m		80
4	1.32	m		1.28	m		43	1.24	m		42
5	3.38	m		3.38	m		82	3.23	dt	14.7, 4.1	80
6	1.32	q	11	1.36	m		—	1.22	m		36
	1.95	m		1.98	m			2.08	m		
7	3.97	t	11	3.96	t	11.3	72	3.97	t	11.0	71
8	2.14	d	14	2.19	m		—	2.20	m		42
	2.85	dd	14, 9	2.85	dd	13.6, 8.7		2.89	dd	17.2, 10.9	
9							—				210
10	2.97	d	9.4	2.96	d	10.2	94	2.97	d	10.6	94
11	2.00	m		2.01	m		32	1.99	m		32
12	0.70	m		0.84	t	9.0	—	0.85	t	8.8	33
	1.17	dd	9.3	1.15	q	12.0		1.15	t	10.3	
13	3.10	t	11	3.15	m		79	3.11	t	10.6	78
14							41				40
15	4.90	d	7	4.92	d	7.8	81	4.90	d	6.5	80
16	5.45	dd	16, 8	5.55	dd	15.4, 9.8	—	5.70	ddd	17.3, 10.8	140
										6.5	
17	6.10	dd	16, 10	6.18	dd	15.4, 9.8	—	5.09	d	17.3	118
								5.17	d	10.5	
18	5.98	dd	16, 10	6.12	dd	15.4, 9.8	—	0.87	d	6.5	12
19	5.69	dd	16, 7	6.22	dd	15.4, 9.8	—	0.98	d	6.5	15
20	2.25	m		6.05	ddd	15.4, 9.8, 1.2					
21	0.95	d	7	5.73	dd	15.4, 6.4	—				
22	0.92	d	7	2.29	m		—				
23	0.98	d	7	0.95	d	6.7	22				
24	0.40	s		0.91	d	6.7	13				
25	1.03	s		0.97	d	6.7	16				
26	0.95	d	7	0.70	s		25	0.74	s		23
27				1.02	s		20	1.01	s		20
28				0.95	d	6.7	22				
1'	4.38	d	8	4.31	d	7.2	107				
2'	2.97	t	10	2.84	t	7.8	86				
3'	3.68	t	10	3.43	m		80				
4'	4.60	m		3.11	m		79				
5'	3.13	t	11	3.05	t	10.8	64				
	3.83	dd	12, 5	3.91	dd	11.3, 5.4					
1''	5.24	d	2	5.18	d	3.6	98				
2''	3.37	br s		3.38	m		79				
3''	3.50	d	12	3.43	m		—				
4''	3.48	br s		3.47	br s		80				
5''	3.88	q	6	4.1	q	6.6	67				
6''	1.09	d	7	1.05	d	6.7	16				
10-OMe	3.19	s		3.19	s		59	3.20	s		58
OMe	3.36	s		3.30	s		59				
OMe	3.38	s		3.38	s		58				
OMe	3.43	s		3.38	s		58				
OMe	3.48	s		3.44	s		62				
OMe				3.47	s		61				
13-OH	1.72	d	11	1.71	d	12.0		1.72	d	12.0	
4-OAc	1.97	s									
Bn-CH ₂								4.36	d	11.5	70
								4.58	d	11.5	
Bn-arom								7.31	s		120, 134

¹H NMR spectra: **1** (400 MHz), **2** (600 MHz).—Denotes not determined.


¹H internal reference (CHD₂CN) was set at 1.9 ppm.

¹³C internal reference (CD₃¹³CN) was set at 118 ppm.

¹³C chemical shifts of **2** and **3b** were roughly determined based on HSQC and HMBC.

acid derived from **4b**, crude NMR spectra measured in CDCl₃ suggested the formation of methyl acetal lactone

(9-*O*-methyl C10-epimer of **11a**). This methyl acetal lactone in CDCl₃ was shaken with aqueous 0.05 M acetic



Scheme 1. Synthesis of **3b** from **4a**. Reagents and conditions: (a) TBDPSCI, Et₃N, DMAP, CH₂Cl₂, 20 °C, 96%. (b) MeI, NaH, CH₂Cl₂, 20 °C, 86%. (c) TBAF, THF, 0 °C, 93%. (d) (COCl)₂, DMSO, CH₂Cl₂, Et₃N, -75 to 0 °C, 83%. (e) DDQ, CH₂Cl₂, H₂O, 20 °C, 87%. (f) NaClO₂, NaH₂PO₄, 2-methyl-2-butene, *i*-PrOH–H₂O (3.5:1), 0 °C, 89%. (g) 2,4,6-trichlorobenzoyl chloride, DIPEA, THF, 20 °C, then DMAP, toluene, 60 °C and (h) CDCl₃ (+HCl), 20 °C, 50% in two steps.

acid and allowed to stand for one day at room temperature. Finally, keto lactone **3b** was obtained in 30% yield from the corresponding secoic acid in two steps. The yields of the other steps were almost same as those in the case from **4a** to **3b**. To determine the stereochemistry of C10 of keto lactone (**3b**) derived from both of **4a** and **4b**, NOE experiments were performed on this keto lactone. Positive NOEs, H6a/H8b, H8b/H11, H10/H12b, H10/Me19, H12a/10-OMe, H12b/Me19, and H13/Me19 were observed by NOESY1D measured in CD₃CN at 20 °C, whereas NOEs, Me19/10-OMe and H10/H11 were not observed (Fig. 2). By these NOEs together with ³J_{H10/H11} (10.6 Hz), Me19, and 10-OMe, and H10 and H11 were suggested to be in anti-conformation for each, as shown in Figure 2. Based on these data, the stereochemistry of C10 of the obtained keto lactone was determined to be in *R*, therefore, C10 in **3a** was suggested to be epimerized, probably via formation of 9,10-enolate under acidic condition. Steric repulsion between 10-OMe and Me19 in **3a** was presumed to induce this epimerization. The NMR data of **3b** were compared with those of **2** (Table 1). The difference of the ¹H NMR chemical shifts of H2–H15, H24–27, 10-OMe, 13-OH of **2** from those of H2–H15, H18–21, 10-OMe, 13-OH of **3b**, respectively, was less than




Figure 2. Key NOEs observed in keto-lactone (**3b**) derived from **4a** and **4b**.

0.1 ppm, except H5 (0.15 ppm), H6a (0.14 ppm), and H6b (0.10 ppm) which were probably due to difference of the substituents at C5. The differences of the ¹³C NMR chemical shifts of C2–C15, C24–C27, 10-OMe of **2** from C2–C15, C18–C21, 10-OMe of **3b**, respectively, were not more than 1 ppm except at C5 (2 ppm). In addition, ³J_{H10/H11} value of **2** (10.2 Hz) was close to that of **3b** (10.6 Hz). According to these data, the planar structure of the aglycon of **1** and **2** was confirmed, and the relative stereostructures of **1** and **2** (10*R*, 13*R*) were determined as shown in Figure 1. To determine the absolute configuration of **2**, CD spectra of **2** and **3b** were measured.¹³ Both of these CD spectra showed a similar characteristic single Cotton effect of negative sign in the region of the transition of ketone (*n*-π*) around 300 nm, which was also shown in the CD spectrum of PA.⁵ Based on these data, the absolute configuration of **2** was determined as same as those of **3b** and PA.

The mouse (ddY, male, 12 g) administrated **2** (2.4 μg, i.p.) did not show any symptoms and survived, suggesting the value of LD₉₉ for **2** was more than 0.2 mg/kg.¹⁵ Compound **3b** did not show cytotoxicity at 20 μM in two cell lines, mouse neuroblastoma cells (Neuro-2a) and human acute monocytic leukemia cells (THP-1), by WST-8 assay (Dojindo, Japan).¹⁴ Cyanobacterium was proposed for the origin of polycavernosides.^{3,16} The structures of **1** and **2** provide information for the biosynthetic pathway or metabolism of polycavernosides, which are necessary for monitoring the occurrence of these human lethal toxins.

Acknowledgements

We are grateful to Professor V. J. Paul, Smithsonian Marine Station at Fort Pierce, for kind supply of *G. edulis*, and to Mr. Akiyoshi Goto, Hokkaido University, for preparation of **4a** and **4b**. This work was supported by the Nagase Science and Technology Foundation, and by

Grants-in-Aid for Scientific Research on Priority Areas from MEXT (18032014), and from JSPS (17580091).

References and notes

1. Yotsu-Yamashita, M.; Haddock, R. L.; Yasumoto, T. *J. Am. Chem. Soc.* **1993**, *115*, 1147–1148.
2. Haddock, R. L.; Cruz, O. L. *Lancet* **1991**, *338*, 195–196.
3. Yotsu-Yamashita, M.; Yasumoto, T.; Yamada, S.; Bajarrias, F. F. A.; Formelozsa, M. A.; Romero, M. L.; Fukuyo, Y. *Chem. Res. Toxicol.* **2004**, *17*, 1265–1271.
4. Yotsu-Yamashita, M.; Seki, T.; Paul, V. J.; Naoki, H.; Yasumoto, T. *Tetrahedron Lett.* **1995**, *36*, 5563–5566.
5. Fujiwara, K.; Murai, A.; Yotsu-Yamashita, M.; Yasumoto, T. *J. Am. Chem. Soc.* **1998**, *120*, 10770–10771.
6. (a) Paquette, L. A.; Barriault, L.; Pissarnitski, D. *J. Am. Chem. Soc.* **1999**, *121*, 4542–4543; (b) Paquette, L. A.; Barriault, L.; Pissarnitski, D.; Johnston, J. N. *J. Am. Chem. Soc.* **2000**, *122*, 619–631.
7. (a) White, J. D.; Blakemore, P. R.; Browder, C. C.; Hong, J.; Christopher, C. M.; Nagornyy, P. A.; Robarge, L. A.; Wardrop, D. J. *J. Am. Chem. Soc.* **2001**, *123*, 8593–8595; (b) Blakemore, P. R.; Browder, C. C.; Hong, J.; Lincoln, C. M.; Nagornyy, P. A.; Robarge, L. A.; Wardrop, D. J.; White, J. D. *J. Org. Chem.* **2005**, *70*, 5449–5460.
8. (a) Perez-Balado, C.; Marko, I. E. *Tetrahedron* **2006**, *62*, 2331–2349; (b) Perez-Balado, C.; Marko, I. E. *Tetrahedron Lett.* **2005**, *46*, 4887–4890; (c) Barry, C. S.; Bushby, N.; Harding, J. R.; Willis, C. L. *Org. Lett.* **2005**, *7*, 2683–2686.
9. Barriault, L.; Boulet, S. L.; Fujiwara, K.; Murai, A.; Paquette, L. A.; Yotsu-Yamashita, M. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2069–2072.
10. (a) Louzao, M. C.; Vieytes, M. R.; Yasumoto, T.; Yotsu-Yamashita, M.; Botana, L. M. *Chem. Res. Toxicol.* **2006**, *19*, 788–793; (b) Cagide, E.; Louzao, M. C.; Ares, I. R.; Vieytes, M. R.; Yotsu-Yamashita, M.; Paquette, L. A.; Yasumoto, T. *Cell. Phys. Biochem.* **2007**, *19*, 185–194.
11. Fujiwara, K.; Amano, S.; Murai, A. *Chem. Lett.* **1995**, 855–856.
12. (a) Inagawa, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989–1993; (b) Hikota, M.; Tone, H.; Horita, K.; Yonemitsu, O. *Tetrahedron* **1990**, *46*, 4613–4628.
13. CD spectral data of **2** and **3b** (MeCN, 22 °C). Compound **2** (0.12 mM): λ_{ext} 210.0 ($\Delta\epsilon$ -1.22), 221.6 (-1.14), 251.0 (-0.47), 272.6 (-0.41), 301.6 (-0.53), 320.0 (-0.33), **3b** (0.4 mM): 226.6 (-0.23), 292.2 (-0.95), 301.0 (-1.13), 309.0 (-1.04), 321.2 (-0.57).
14. Ishiyama, M.; Tominaga, H.; Shiga, M.; Sasamoto, K.; Ohkura, Y.; Ueno, K.; Watanabe, M. *In Vitro Toxicol.* **1995**, *8*, 187–190.
15. LD₉₉ for PA was reported as 0.2–0.4 mg/kg.¹
16. Yasumoto, T. *Chemical Record* **2001**, *1*, 228–242.